What is the impact of neoadjuvant chemoradiation on outcomes in gastro-intestinal cancer?

C. Mariette(Hôpital Claude Huriez), C. Penna(Université Paris-Sud), Guillaume Piessen(Centre Hospitalier Universitaire de Lille), Pascale Mariani(Université Paris Sciences et Lettres), Antoine Brouquet(Bicêtre Hospital), Andrea Laurenzi(Hôpital Paul-Brousse), António Sá Cunha(Assistance Publique – Hôpitaux de Paris), Anne de la Rochefordière(Institut Curie), Dimitri Tzanis(Université Paris Cité)
Journal of Visceral Surgery
June 1, 2017
10.1016/j.jviscsurg.2017.05.004
Cited by 9

Related Papers

Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid vs Gemcitabine Following Pancreatic Cancer Resection
|JAMA|2010|1.4k
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2022|1.4k
Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2016|1.1k
Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy versus cytoreductive surgery alone for colorectal peritoneal metastases (PRODIGE 7): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|812
Is There a Possibility of a Cure in Patients With Colorectal Peritoneal Carcinomatosis Amenable to Complete Cytoreductive Surgery and Intraperitoneal Chemotherapy?
|Annals of Surgery|2013|270